Clinical trial
Risperdal Consta for Bipolar Disorder
NCT00177164 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00177164 |
|---|---|
| Title | Risperdal Consta for Bipolar Disorder |
| Official title | A Random Assignment,Parallel Group, Open Label Comparison of Clinical Outcomes and Resource Utilization Among Bipolar Disorder Patients Receiving Either Long Acting Injectable Risperidone Microspheres (Risperdal Consta® ) or Other Second Generation Oral Antipsychotic Agents: A 15 Month Study |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Janssen Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bipolar I Disorder |
| Intervention type | Drug |
| Interventions | Injectable Risperidone (Consta) or oral antipsychotic |
| Enrollment | 50 |
| Start date | Nov 1, 2003 |
| Primary completion | Mar 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | Sep 15, 2005 |
| Last update posted | Apr 19, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: